Clinical Trial Update: Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1 study of ANGEL, an EBV-specific cytotoxic T-cell therapy for relapsed Epstein-Barr virus-associat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Plasma Cell Neoplasm

Drugs mentioned

• ANGEL EBV-specific cytotoxic T-cells (EBV-specific cytotoxic T cells)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED